Problem
Refusal to market new drugs
Other Names:
Refusal to test new drugsDenial of potential health aids
Stopping development of medical cures
Nature:
New drugs that can counteract tuberculosis are ready for testing, but the American pharmaceutical industry refuses to pay to test and market them due to the costs involved, which it claims are $200 million US. It says that the US market for the drug is too small to recover its costs, entirely ignoring about 1.75 billion tubercular people outside its borders who need the drugs. There is no American or global agency that can legally force the pharmaceutical companies to sell their products. Broader Problems:
Refusal to sellApplied double standardsBlocked global marketingCommercial exploitation of healthRefusal to provide medical treatmentRestrictive practices in trade in pharmaceutical productsIneffective self-regulation in the pharmaceutical and medical devices industries Related Problems:
Suppression of scientific information Aggravates:
MalariaTuberculosisInadequate primary health careWeakness in trade among developing countries Subject(s):
Medicine → Medicine Medicine → Sexually transmitted diseases
Commerce → Market
Societal Problems → Deprivation
Health Care → Health
Health Care → Treatment
Health Care → Pharmacy
Development → Development
Development → Potential
Related UN Sustainable Development Goals:
Problem Type:
G: Very specific problems Date of last update
04.10.2020 – 22:48 CEST